CXCL12 and heart failure: Many of the effects of DPP-4 inhibitors in large-scale clinical trials, including their effects on atherosclerotic ischemic events, heart failure, sodium excretion, albuminuria and glomerular function may be meaningfully influenced by their actions to enhance of the endogenous stem-cell chemokine, SDF-1.